T. C. M. Morris

1.4k total citations
35 papers, 886 citations indexed

About

T. C. M. Morris is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, T. C. M. Morris has authored 35 papers receiving a total of 886 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in T. C. M. Morris's work include Multiple Myeloma Research and Treatments (10 papers), Peptidase Inhibition and Analysis (6 papers) and Cancer Treatment and Pharmacology (5 papers). T. C. M. Morris is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Peptidase Inhibition and Analysis (6 papers) and Cancer Treatment and Pharmacology (5 papers). T. C. M. Morris collaborates with scholars based in United Kingdom, United States and Netherlands. T. C. M. Morris's co-authors include Mary Drake, Lisa Crawford, H. Denis Alexander, D Niederwieser, Tapani Ruutu, Alexandra E. Irvine, Brian Walker, Dharminder Chauhan, Kenneth C. Anderson and Huib Ovaa and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

T. C. M. Morris

34 papers receiving 867 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. C. M. Morris United Kingdom 16 440 364 283 154 115 35 886
Jiří Vorlíček Czechia 17 227 0.5× 492 1.4× 268 0.9× 98 0.6× 147 1.3× 98 969
Ahmad Ahmadzadeh Iran 15 388 0.9× 174 0.5× 230 0.8× 147 1.0× 68 0.6× 67 805
Fotini Tzortzatou‐Stathopoulou Greece 20 565 1.3× 328 0.9× 213 0.8× 122 0.8× 83 0.7× 67 1.3k
R. Lerner Sweden 17 211 0.5× 261 0.7× 147 0.5× 145 0.9× 188 1.6× 29 745
Ruggiero Fumarulo Italy 17 458 1.0× 241 0.7× 203 0.7× 43 0.3× 172 1.5× 33 981
R. Tang France 16 314 0.7× 101 0.3× 349 1.2× 201 1.3× 225 2.0× 23 924
Shigeru Takamoto Japan 15 181 0.4× 220 0.6× 115 0.4× 92 0.6× 95 0.8× 46 668
Debra Zack United States 24 561 1.3× 212 0.6× 349 1.2× 57 0.4× 567 4.9× 35 1.7k
T Akabane Japan 18 245 0.6× 276 0.8× 181 0.6× 99 0.6× 531 4.6× 87 1.1k
Zhimin Zhai China 16 217 0.5× 393 1.1× 160 0.6× 51 0.3× 287 2.5× 49 910

Countries citing papers authored by T. C. M. Morris

Since Specialization
Citations

This map shows the geographic impact of T. C. M. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. C. M. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. C. M. Morris more than expected).

Fields of papers citing papers by T. C. M. Morris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. C. M. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. C. M. Morris. The network helps show where T. C. M. Morris may publish in the future.

Co-authorship network of co-authors of T. C. M. Morris

This figure shows the co-authorship network connecting the top 25 collaborators of T. C. M. Morris. A scholar is included among the top collaborators of T. C. M. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. C. M. Morris. T. C. M. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Egan, Philip, et al.. (2022). IgD multiple myeloma: biology, diagnosis, and treatment. Leukemia & lymphoma. 63(14). 3433–3437. 1 indexed citations
2.
3.
Crawford, Lisa, et al.. (2010). Methods for measuring proteasome activity: Current limitations and future developments. Leukemia Research. 34(11). 1403–1409. 34 indexed citations
4.
Crawford, Lisa, et al.. (2010). Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis. Journal of Leukocyte Biology. 88(4). 807–811. 47 indexed citations
5.
Morris, T. C. M., Paul Kettle, Mary Drake, et al.. (2008). Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. British Journal of Haematology. 143(3). 349–354. 19 indexed citations
6.
Morris, T. C. M., et al.. (2005). Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population‐based survey*. British Journal of Haematology. 128(4). 510–512. 16 indexed citations
7.
Rao, Sheela, David Watkins, David Cunningham, et al.. (2004). Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Annals of Oncology. 15(9). 1413–1418. 37 indexed citations
8.
9.
Coyle, Vicky M., et al.. (2004). Catheter-related bloodstream infection in adult haematology patients: catheter removal practice and outcome. Journal of Hospital Infection. 57(4). 325–331. 26 indexed citations
10.
Kettle, Paul, et al.. (2003). Quantitation of Monoclonal Plasma Cells in Bone Marrow Biopsies in Plasma Cell Dyscrasia. Analytical Cellular Pathology. 25(4). 167–171. 4 indexed citations
11.
12.
13.
McCluggage, W. Glenn, Mark Catherwood, H. Denis Alexander, et al.. (2002). Immunohistochemical expression of CD10 and t(14;18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B‐cell lymphoma. Histopathology. 41(5). 414–420. 25 indexed citations
14.
Morris, T. C. M., et al.. (2001). Phase II Trial of Clarithromycin and Pamidronate Therapy in Myeloma. Medical Oncology. 18(1). 79–84. 18 indexed citations
15.
Cosby, S. Louise, et al.. (2000). Quantitative deficiency of monocyte‐specific esterase (MSE) mRNA in monocyte esterase deficiency (MED). British Journal of Haematology. 110(3). 699–703. 4 indexed citations
16.
McNerlan, Susan, Irene Maeve Rea, H. Denis Alexander, & T. C. M. Morris. (1998). Changes in Natural Killer Cells, the CD57CD8 Subset, and Related Cytokines in Healthy Aging. Journal of Clinical Immunology. 18(1). 31–38. 62 indexed citations
17.
Alexander, H. Denis, et al.. (1998). Familiality of monocyte esterase deficiency in patients on continuous ambulatory peritoneal dialysis. Renal Failure. 20(4). 607–612. 2 indexed citations
18.
Morris, T. C. M., et al.. (1997). Renal Failure and Esterase-Negative Monocytes. Renal Failure. 19(1). 121–128. 3 indexed citations
19.
Morris, T. C. M., et al.. (1991). Lactoferrin inducible monocyte cytotoxicity defective in esterase deficient monocytes. British Journal of Haematology. 77(3). 287–290. 19 indexed citations
20.
Morris, T. C. M., et al.. (1989). THE INTIMATE RELATIONSHIP OF MYELOFIBROSIS AND MYELOMA: EFFECT OF THERAPY. British Journal of Haematology. 73(2). 269–270. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiří Vorlíček Breakdown of academic impact, for papers by Ahmad Ahmadzadeh Breakdown of academic impact, for papers by Fotini Tzortzatou‐Stathopoulou Breakdown of academic impact, for papers by R. Lerner Breakdown of academic impact, for papers by Ruggiero Fumarulo Breakdown of academic impact, for papers by R. Tang Breakdown of academic impact, for papers by Shigeru Takamoto Breakdown of academic impact, for papers by Debra Zack Breakdown of academic impact, for papers by T Akabane Breakdown of academic impact, for papers by Zhimin Zhai
Rankless by CCL
2026